Skip to content

Ketamine: all studies

Page 82 of 448: studies 811 to 820 of 4,475, newest first. Back to the ketamine overview

Research

Ketamine for unipolar depression: A systematic review of efficacy and safety.

Australasian Psychiatry June 1, 2025 Tharshanan Edwin Peiris, Amrit Pokhrel, Yuvaraj Paudel 2 citations

BackgroundUnipolar depression is a prevalent mental health disorder with persistent, treatment-resistant symptoms. Traditional antidepressants take weeks to show effects, underscoring the need for faster alternatives. Ketamine, originally an anaesthetic, has emerged as a rapid-acting antidepressant.ObjectiveThis systematic review evaluates ketamine's efficacy and safety in unipolar...

Etomidate versus ketamine for in-hospital rapid sequence intubation: a systematic review and meta-analysis.

European Journal of Emergency Medicine June 1, 2025 Mohamed Aziz Daghmouri, Mohamed Ali Chaouch, Mohamed Noomen et al. 8 citations

Rapid sequence intubation (RSI) is a critical procedure in emergency and intensive care settings. Etomidate has been favored for its hemodynamic stability; however, concerns about adrenal insufficiency have prompted interest in ketamine as an alternative induction agent. This systematic review and meta-analysis aimed to compare the effects of etomidate vs ketamine on 30-day survival and other...

Impact of Medical Comorbidities on Ketamine and Esketamine Treatment Effectiveness for Posttraumatic Stress Disorder and Depression: A Clinical Outcomes Analysis from the VA San Diego Healthcare System.

CNS Drugs June 1, 2025 Sijia Zhang, Houtan Afshar, Peter J. Colvonen et al. 1 citation

Ketamine and esketamine are increasingly used to manage treatment-resistant depression and have also been shown to reduce symptoms of posttraumatic stress disorder (PTSD). Little is known about how common comorbidities in the veteran population, such as traumatic brain injury (TBI) or obstructive sleep apnea (OSA), may influence ketamine and esketamine treatment outcomes. In this retrospective...

DOI: 10.1007/s40263-025-01180-w (opens in new tab) Full text (opens in new tab) Ketamine therapy Veterans mental health PTSD Treatment Depression treatment +1

Novel mechanisms underlying rapid-acting antidepressants: ketamine-like compounds, neurosteroid GABAkines, and psychedelics.

Drug Discovery Today June 1, 2025 Sara Castanheira, Catarina Vale Gomes, Joana Bicker et al. 9 citations

The discovery of the rapid antidepressant action of ketamine accelerated the identification of new molecules that are associated with fast and prolonged relief of depressive symptoms. As a result, a new group of antidepressants have emerged, some of them already approved for clinical use, classified as rapid-acting antidepressant drugs (RAADs). Potentiation of brain-derived neurotrophic factor...

The Nine Lives of Ketamine: From CI-581 to Present Day Clinical Application-Commentary on Domino et al.

Clinical Pharmacology & Therapeutics June 1, 2025 Evan D Kharasch 4 citations

The classic article by Domino et al. was the first clinical report and presented the first-in-human study of what would become the drug ketamine. Ketamine has become an analgesic, anesthetic, antidepressant, and drug of misuse. It remains today the only "dissociative anesthetic". It has challenged classical pharmacologic theory and drug development paradigms. The first report on CI-581 could...

DOI: 10.1002/cpt.3634 (opens in new tab) Full text (opens in new tab) Anesthesia Psychopharmacology Mental health Drug development

Impact analysis of expanded access to ketamine for treatment-resistant depression.

Journal of comparative effectiveness research June 1, 2025 Thanh Lu, Sophia D'Angelo, Zohra Tayebali et al.

Aim: This study aimed to estimate the economic impacts of expanded access to ketamine relative to electroconvulsive therapy (ECT) by offering intravenous ketamine to US patients with nonpsychotic treatment-resistant depression (TRD) and moderate-to-severe depression. Materials & methods: A population-level Markov simulation model with key parameters from a randomized trial was used to simulate...

Ketamine in Neurocritical Care: New Potentials and Perspectives.

Cureus June 1, 2025 Rudin Domi, Alma Cani, Asead Abdyli et al. 3 citations

Ketamine is an intravenous hypnotic anesthetic that acts primarily by inhibiting N-methyl-D-aspartate (NMDA) receptors, leading to a range of effects, including hypnosis, analgesia, anticonvulsant activity, anti-inflammatory action, and neuroprotection. Initially, there were concerns that ketamine might elevate intracranial pressure. However, these worries have since been dispelled, leading to...

DOI: 10.7759/cureus.85456 (opens in new tab) Full text (opens in new tab) Anticonvulsant Neurocritical care Sedation • neuroprotection +3

Trends in ketamine use among nightclub attendees in New York City, 2017-2024.

International Journal of Drug Policy June 1, 2025 Joseph J Palamar 7 citations

Ketamine-related poisonings and law enforcement seizures have been increasing in the United States, but population surveys suggest that recreational use has been rare with trends being relatively stable. This study aimed to estimate trends and correlates of use among nightclub attendees-a population known for high prevalence of party drug use. Adults entering randomly selected nightclubs in New...

DOI: 10.1016/j.drugpo.2025.104825 (opens in new tab) Full text (opens in new tab) Drug trends Hallucinogens Nightclub attendees Nightlife culture +3

Converging pathways: shared brain circuitry engaged by monoaminergic antidepressants, ketamine and psilocybin

bioRxiv (Cold Spring Harbor Laboratory) May 30, 2025 Pavel Osten, K Sunny Joseph, Jane Collins et al. preprint

Abstract Ketamine has transformed depression treatment by providing therapeutic relief within a single day, unlike monoaminergic antidepressants that require weeks to take effect. Here, we conducted whole-brain screening in mice to compare drug-evoked c-fos expression—acting as a marker of brain activity leading to protein synthesis-dependent forms of plasticity—following treatment with...

In adult patients presenting to ED with severe acute pain, is intranasal ketamine as effective as intravenous opiates for pain reduction?

Emergency Medicine Journal May 30, 2025 Khilan Santilal, Rhea Saldanha 1 citation

This systematic review assessed whether intranasal (IN) ketamine is as effective as intravenous (IV) opiates for adults presenting to the ED with acute severe pain. EMBASE and Medline were searched, using relevant search terms, identifying four studies relevant to our three-part question. Key findings, as well as study weaknesses, were presented in a table. In summary, our results indicate that...

DOI: 10.1136/emermed-2025-215080 (opens in new tab) Full text (opens in new tab) Emergency medicine Pain management analgesia Pain control Ketamine ketamine therapy +5